David is the forward-thinking CEO of Proscia, an innovative startup that revolutionizes our understanding of diseases such as cancer through cutting-edge digital pathology and AI solutions. With his background in computational biology, David embarked on an entrepreneurial journey and established Proscia in 2014, driven by groundbreaking research conducted at Johns Hopkins University.
Through relentless dedication and a passion for innovation, Proscia has emerged as a market leader in the field, earning accolades for its pioneering work. The company works with major diagnostic laboratories and has secured contracts with 14 of the top 20 pharmaceutical companies, solidifying its position in the industry. Additionally, Proscia has garnered substantial support, raising an impressive $75M in funding to further its mission.
David’s exceptional vision and achievements have not gone unnoticed. He has been recognized as a trailblazer, earning a coveted spot on Forbes 30 Under 30 list. Holding a degree in Biomedical Engineering from Johns Hopkins University, David possesses the expertise and knowledge required to steer Proscia towards continued success in the realms of digital pathology, startups, innovation, and AI.
What led you to found Proscia?
What proved to be most successful in growing the company?
What is the biggest challenge you’ve encountered as CEO?
What’s the best advice you’ve ever received when it comes to building a company?
How have you challenged the status quo to drive change in the practice of pathology?
What are the challenges with the traditional practice of pathology?
How is digital pathology helping to improve outcomes for cancer patients?
How is pathology data helping to advance the quest for precision medicine?
David uses a Shure Mv7 and earbuds on every podcast appearance to ensure the quality of the audio